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Structured Summary

Author Manuscript

Background—Adherence to antiretroviral therapy (ART) is a necessary condition to the
improvement of HIV patient health and public health through ART. This study sought to determine
the comparative effectiveness of different interventions for improving ART adherence among HIVinfected persons living in Africa.
Methods—We searched for randomized trials that evaluated an intervention to promote
antiretroviral adherence within Africa. We created a network of the differing interventions by
pooling the published and individual patient data for comparable treatments and comparing them
across the individual interventions using Bayesian network meta-analyses. Outcomes included
self-reported adherence and viral suppression.

Author Manuscript

Findings—We obtained data on 14 randomized controlled trials, involving 7,110 patients.
Interventions included daily and weekly short message service (SMS) messaging, calendars, peer
supporters, alarms, counseling, and basic and enhanced standard of care (SOC). For self-reported
adherence, we found distinguishable improvement in adherence compared to SOC with enhanced
SOC (odds ratio [OR]: 1.46, 95% credibility interval [CrI]: 1.06–1.98), weekly SMS messages
(OR:1.65; 95% CrI: 1.25–2.18), counseling and SMS combined (OR:2.07; 95% CrI: 1.22–3.53),
and treatment supporters (OR:1.83; 95% CrI:1.36–2.45). We found no compelling evidence for the
remaining interventions. Results were similar when using viral suppression as an outcome,
although the network of evidence was sparser. Treatment supporters with enhanced SOC (OR:
1.46; 95% CrI: 1.09–1.97) and weekly SMS messages (OR:1.55; 95% CrI: 1.00–2.39) were
significantly superior to basic SOC.
Interpretation—Several recommendations for improving adherence are unsupported by the
available evidence. These findings should influence guidance documents on improving ART
adherence in poor settings.

Introduction
Author Manuscript

Antiretroviral therapy (ART) has clinical and public health benefits by decreasing morbidity
and mortality of HIV-infected individuals as well as HIV transmission to sex partners.1
Many patients experience difficulties in taking their ART at some time in their life and may
take it only sporadically or take drug holidays.2 There are many possible reasons for not
taking ART, including a myriad of social, personal and structural factors.3, 4 Promoting
adherence to ART is considered one of the chief public health concerns for populations
living with HIV infection.5
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Despite the importance of achieving and maintaining high rates of ART adherence, few
interventions have proved successful among those experiencing difficulties.6, 7 In Africa,
where most people with HIV infection reside, there are specific social, structural or health
system-related barriers that are particularly prevalent including food insecurity, stigma,
supply chain interruptions, and a lack of human health resources.8 Previous systematic
reviews have identified potentially effective interventions, but have not evaluated their
effectiveness in a statistical way.7, 9, 10

Author Manuscript

The past decade has seen important progress in the field of evidence synthesis, particularly
with the popularization of network meta-analysis (NMA).11–14 In traditional meta-analysis,
all included studies compare the same intervention with the same comparator. NMA extends
this concept by including multiple pairwise comparisons across a range of interventions and
provides estimates of relative treatment effects on multiple treatment comparisons for
comparative effectiveness purposes based on direct and/or indirect evidence. Here, direct
evidence for the effect of treatment B vs. A would correspond to the evidence familiar to us
in pairwise meta-analysis, combining all head to head comparisons. Indirect evidence
corresponds to all common comparisons of B vs. A through common comparators, such as
standard of care. Thus, NMA allows for inference between two interventions even in the
absence of head-to-head evidence. The conditions required for conducting these analyses
resemble those of traditional meta-analysis, however, they require that direct and indirect
evidence be in agreement, a condition called consistency. Therefore, we aimed to evaluate
what ART adherence interventions have been conducted in the African setting. We used a
NMA approach to draw from both direct and indirect evidence from randomized trials.

METHODS
Author Manuscript

This study has been designed and reported according to the pending Preferred Reporting
Items for Systematic Reviews and Meta-Analysis (PRISMA) extension to network metaanalyses.15 The protocol for this study is available from the authors upon request.
Selection Criteria
The populations, interventions, comparisons, outcomes and study designs considered for
review are listed in Box 1. All RCTs must have included an intervention targeted to increase
ART adherence, and targeted to increase ART adherence over a minimum of a 3-month
period, and report ART adherence as an outcome. We restricted trials to African countries to
avoid issues of dissimilarity that arise from variations in HIV risk groups.
Search Strategy

Author Manuscript

We conducted a systematic search of the medical literature for relevant randomized clinical
trials that described interventions to improve adherence to ART among HIV-positive
patients, using terms for “HIV”, “ART”, “adherence” and “Africa”. The search was
conducted using the following electronic databases: AMED, CINAHL, EMBASE,
MEDLINE (via PubMed), and Clinicaltrials.gov from inception to October 2014. The
complete search strategy used to identify studies is available in the web appendix. Two
investigators (KM, ML) reviewed all abstracts and full-text articles. We contacted all study
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authors and requested the individual data on patients achieving adherence and viral
suppression. We did not set any restriction based on publication date and included all studies
available as of October 2014.
Data extraction and Variable Definitions
Using a standard data sheet, we extracted the following data from articles that met the
inclusion criteria: 1) trial duration; 2) trial location; 3) year of publication; 4) rate of loss to
follow-up; 5) ART experience; 6) proportion of women; 7) median age; 8) sample size
within each treatment arm; 9) treatment within each arm; 10) count of participants attaining
adherence in each arm; 11) the measures of adherence used; 12) the number retained
throughout the study. When data were unavailable or only partial, we requested data directly
from authors. Data extraction from eligible studies was done independently and in duplicate.

Author Manuscript

We grouped treatment arms using the following categories: 1) standard of care (SOC); 2)
enhanced standard of care (eSOC); 3) alarm; 4) eSOC + alarm; 5) eSOC + calendar; 6) daily
SMS; 7) weekly SMS; 8) eSOC + weekly SMS; 9) eSOC + treatment supporter; 10) SOC +
treatment supporter. Definitions for treatment groupings are provided in Box 1. In brief,
SOC consisted of regular ART pick-ups including consultations with physician or
pharmacist. In some cases adherence counseling was reported as part of SOC, and in others
as a specific intervention, particularly when counselors were involved. We did not
differentiate such cases and considered interventions that included adherence counseling in
addition to SOC, either directly from the health practitioner or from adherence counselors, to
be eSOC. Finally, we did not differentiate treatment supporters that assisted in directly
observed treatment (DOT) and those who provided other assistance.

Author Manuscript

The primary outcome was adherence as defined by the proportion of patients in each RCT
arm meeting the trial-defined adherence criteria. Adherence was measured using the
percentage of pills taken with various cut-off values and when multiple measures were
reported they were favored in the following order: 95%, 90%, 80%, and 100%. We chose to
place the 100% cut-off last in our order because it over-estimates poor adherence.16 The
proportion of patients achieving viral suppression was collected as a secondary outcome. All
outcomes were extracted at the end of study period.
Data Synthesis and Analysis

Author Manuscript

To inform comparative effectiveness between all interventions, we conducted a Bayesian
network meta-analysis (NMA) using all ten intervention types.17 This method provides
better comparative evidence than pair-wise meta-analysis because it combines direct (i.e.,
head-to-head comparisons) and indirect evidence (comparisons across a common
comparator) and in doing so increases the power of statistical comparisons while allowing
for inferences of comparative effects between interventions that have not been compared
head-to-head.13, 18 In estimating the efficacy parameters using Markov chain Monte Carlo
methods, we used a burn-in of 20,000 iterations and 40,000 iterations for estimation.
Convergence was assessed used Gelman-Rubin diagnostics. Priors were normally
distributed, centered at zero, with large variance for all parameters except the probability of
adherence and viral suppression, which both used a binomial prior distribution.

Lancet HIV. Author manuscript; available in PMC 2016 November 04.

Mills et al.

Page 5

Author Manuscript

We performed edge-splitting to assess the consistency of direct and indirect evidence for
interventions for which both types of information was available.19 We assessed the deviance
information criterion (DIC) as a measure of model fit that penalizes for model complexity.20
We modeled comparative log odds ratios using the conventional logistic regression NMA
setup.17 All results for the network meta-analysis are reported as posterior medians with
corresponding 95% credibility intervals (CrIs), the Bayesian analog of classical confidence
intervals. Sensitivity analyses included period of trial follow-up and choices of adherence
thresholds for measurement.
All analyses were conducted using WinBUGS version 1.4 (Medical Research Council
Biostatistics Unit, Cambridge) and R version 3.0.1 (http://www.r-project.org/).
Role of the funding source

Author Manuscript

The sponsor of the study had no role in study design, data collection, data analysis, data
interpretation, or writing of the report. The corresponding author had full access to all the
data in the study and had final responsibility for the decision to submit for publication.

RESULTS

Author Manuscript

We identified 151 relevant abstracts (Figure 1). Of these, 118 publications did not meet our
inclusion criteria. Of the 33 further reviewed manuscripts, we excluded 20 publications (as
not RCTs [n=12],21–32 not adherence interventions [n=1],33 did not report adherence after 3
months [n=1],34 irrelevant interventions [n=2],35, 36 outcome not reported [n=1],37 cluster
study design [n=1],38 paediatric population [n=1],39 or sub-study of another included trial
[n=1]40); these studies are listed in Appendix 2. We included the remaining 13 publications,
along with an additional poster provided following the search. Together, these described 14
RCTs in our analyses (Table 1).38, 39, 41–53 Individual level data were available for 9 of the
RCTs.
Adherence

Author Manuscript

Our primary network includes data from 13 studies (n = 5,310), comprising 30 treatment
arms. Figure 2 represents the network of evidence for ART adherence interventions
contained in the included studies. Nodes represent each included intervention; numbers on
each edge represent the number of corresponding trials. Follow-up time for adherence
outcomes varied from 17 to 192 weeks. Various measures were used to report adherence.
The most common measure reported was the proportion of patients in each arm with at least
95% adherence by self-report; ten studies reported this operationalization.41–46, 48, 51–53
Four studies reported the proportion of patients with no missed dose or 100%
adherence,41, 46, 47, 53 and two reported the proportion with at least 90% adherence.49, 50
In order to assess consistency across the network, we calculated direct and indirect evidence
for each comparison for which both types of evidence were available. The results of this
edge-splitting exercise are presented in Appendix 3. Results were consistent between direct
and indirect evidence, suggesting that conditions required for these analyses were met.
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Table 2 presents odds ratios (OR) and 95% credibility intervals (CrI) for all pairwise
comparisons of adherence interventions. Enhanced SOC performed better than basic SOC.
Weekly SMS (with or without eSOC) was associated with better adherence than SOC alone.
The combination of eSOC with a treatment supporter performed better than SOC, eSOC, or
the alarm alone. Weekly SMS (without eSOC) was associated with higher adherence than
daily SMS (OR 1.56, 95% CrI 1.01–2.40); the difference between weekly SMS with eSOC
compared to daily SMS was not statistically or operationally important. No other pairs of
adherence interventions were found to be statistically different. Further inference can be
drawn from table 2. The combination of the effect estimates for eSOC and weekly SMS was
2.41, suggesting an additive effect of eSOC and weekly SMS.

Author Manuscript

We additionally examined the follow-up time and choice of adherence measurement as
potential sources of heterogeneity through sub-analyses. Neither factor was found to
influence the comparative efficacy measurements. As a sensitivity analysis for the adherence
outcome, an additional NMA was conducted using the number remaining in the study (perprotocol) rather than intention to treat; the results are given in Appendix 4. Comparisons of
eSOC+alarm versus SOC, eSOC, and alarm alone were all found to be statistically
significant in the per-protocol analysis, suggesting differential loss-to-follow up among these
treatment arms. Appendix 5 displays the pairwise pooled estimates compared with the
network estimates.
Viral suppression

Author Manuscript

Our secondary network meta-analysis included data from 13 treatment arms in six
studies41, 44, 48, 51, 52, 54 (N = 2,738). The network of evidence contained in these studies is
shown in Figure 3. Six interventions were included in the studies with available viral
suppression data: SOC, eSOC, alarm, weekly SMS, eSOC+treatment supporter, and SOC
+treatment supporter. For studies where multiple time points were reported, the same time
points were selected as in the adherence analysis where possible. Four studies reported the
number of patients who had achieved plasma HIV RNA suppression (< 400 copies/
mL),44, 51, 52, 54 one study reported the number of patients on-study with viral failure
defined as ≥400 copies/mL,41, 54 and one study reported the number of patients on-study
with viral failure defined as ≥5,000 copies/mL.42 We modeled viral suppression with an onstudy analysis that treating measured lack of failure as equal to suppression regardless of the
cutoff point.

Author Manuscript

As with adherence, we performed edge-splitting in order to assess consistency between
direct and indirect evidence across the network. The results are shown in Appendix 6; results
were reasonably consistent, although there was a greater (but still non-significant) OR found
for eSOC vs SOC with direct evidence than by indirect evidence alone.
Table 3 presents ORs and 95% CrI for viral suppression for all pairwise comparisons of
interventions with available viral suppression data. Both weekly SMS (OR: 1.55; 95% CrI:
1.01–2.38) and eSOC+treatment supporter (OR: 1.46; 95% CrI: 1.09–1.97) were associated
with higher suppression rates than SOC, or SOC+treatment supporter. No other pairs of
adherence interventions were found to be different with respect to viral suppression.
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DISCUSSION

Author Manuscript

Our analysis examined all RCTs conducted to evaluate interventions to promote adherence
to antiretroviral therapy in Africa. We found compelling evidence that enhanced standard of
care improved patient adherence. This was further improved when combined with weekly
SMS messages and treatment supporters. In fact, the combination of enhanced standard of
care, a cognitive intervention, and weekly SMS messaging, a behavioral intervention,
appeared to be additive in nature, a novel finding that could not be tested in the individual
studies in the current evidence base. Our findings also provide evidence that there is
insufficient evidence to support alarms, daily SMS messages, and calendars. These findings
are at odds with some previous reports and meta-analyses and the difference may be partly
explained by the analytical approach we used.10, 55 Our study found a large treatment benefit
for weekly SMS messages but not for daily SMS messages. It is possible that there is a doseeffect wherein less is more as, supportive SMS messages may become a reminder when too
frequent, and reminders do not appear to support adherence.56

Author Manuscript

Our findings have operational and clinical implications. For example, we found a large,
additive treatment benefit of adding weekly SMS messages to enhanced standard of care.
Our study suggests that combining cognitive and behavioural interventions could maximize
the intervention efficacy. Although weekly SMS messaging is a relatively low cost
intervention, it requires that patients have access to a cell phone and can receive SMS
messages confidentially.57 Given the high penetration of mobile technology in low-income
settings such as sub-Saharan Africa, India, etc. our findings may have global relevance and
implications. Nonetheless, there remain features of the weekly SMS messaging intervention
that need be further researched and determined by program managers, such as whether
patients will be able to respond to the messages and reach a care provider (“two way”
messages) or not (“one way”), and what content should be sent.58 The trials considered in
this study differed in this regard.

Author Manuscript

Similarly, we found a large treatment effect of a treatment supporter in combination with
enhanced standard of care. However, this intervention would be inappropriate where
confiding one’s HIV status to another person is not possible.48 Our finding that treatment
supporters importantly increase adherence is at odds with some reviews examining treatment
supporters and directly observed therapy.55, 59 Other reviews have included populations with
competing mental health concerns and have used standard meta-analysis approaches. The
use of a network meta-analysis allows for greater power and greater precision in the analysis
and this appears to explain why our findings are significant and other’s findings are not.60
Prior work has documented the feasibility, acceptability, and potential efficacy of treatment
supporters as a community-based intervention (i.e. wide spread use of this method
throughout the community).48, 61, 62
Across HIV programs, treatment supporters can be defined in several ways and this has
created a debate within the implementation field as to what extent they should be promoted.
Treatment supporters range from paid employees, such as accompagnateurs in Partners in
Health projects, to unpaid family and friends in other programs.55 Similarly, treatment
supporters may offer assistance that ranges from emotional support and reminding patients
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to adhere to therapy or more intensively offer services that may include directly observed
therapy (DOT) and clinical monitoring. The evidence to support DOT is not convincing,55
but the evidence for social support that may include adherence discussions and reminders is
much more broadly accepted. It is unlikely that this analysis will settle the issue.

Author Manuscript

There are several strengths and limitations to consider in our analysis. Strengths include our
extensive search, communication with trialists, and the statistical approach we used. We held
meetings of those working in the field to identify any additional trials and received
individual patient level data where possible. Our statistical approach allows for greater
power than standard meta-analysis as it incorporates data from both indirect and indirect
evidence (see Appendix 4). Limitations of our review to generalizability include the lack of
available data in specific populations such as HIV-infected children, adolescents, pregnant
women, prisoners, MSM etc. that could be inserted into the network. We found a low
number of studies for each individual intervention and so further confirmatory RCTs are
warranted. We considered including studies from more developed settings, however, given
that the HIV epidemic in Africa is substantially different than in other continents (in terms
of a generalized epidemic) and that most RCTs in other settings have been directed at
individuals with competing mental health concerns (e.g. addictions) or marginalized persons
(e.g. homeless, youth, etc.), we believe that restricting the analysis to Africa is necessary to
meet the conditions required for the methodology employed for our analyses.

Author Manuscript
Author Manuscript

An important limitation to our study pertains to treatment definitions. As opposed to drugs,
these behavioral and cognitive interventions varied across studies. This is especially true of
eSOC, defined as SOC with an educational component, because the education component
varied according to content and whether it was delivered in-group or one-on-one.
Nonetheless, statistical heterogeneity was moderate, suggesting that this was a minimal
threat. Limitations to external validity include the exclusion of pediatric populations from
the network, but this was by design given that adherence among children is typically a
caregiver issue rather than patient-motivated. In addition, we considered various definitions
of adherence and viral failure as equivalent. We considered self-reported adherence and
more objective forms (such as medication event monitoring systems [MEMS]) as equivalent.
However, self-report may over-estimate adherence.63 There were an insufficient number of
studies to assess this using a sensitivity analysis. We included only RCTs and it is possible
that there are other interventions that have been conducted at the program level in a nonresearch manner, that also have important treatment benefits. We are aware that interventions
to promote retention in programs differ across and within countries and we acknowledge that
some programs may use different adherence strategies also.64 Finally, we considered the
RCT period as equivalent across studies and conducted a sensitivity analysis examining for
duration of follow-up. Although we did not identify time as an effect modifier, it is likely
that adherence will wane with any intervention over the long term.65, 66
Network meta-analysis should only be considered as valid as the individual comparisons
within a network. In our network, several of the nodes in the network are informed by just
one or two trials and at most by five trials. In general, the more trials in a comparison, the
greater the power to detect treatment effects.18, 67 Although we cannot add trials to our
network, because no other trials exist, we can assess whether the comparisons are believable
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by assessing the transitivity of direct versus indirect evidence.68 When we assessed pairwise
estimates versus network estimates we found no evidence of inconsistency between the
direct and indirect evidence. This increases our confidence that the network is sufficiently
robust that the findings are unlikely to be spurious.68 As further evidence accumulates, this
will further strengthen inferences from the network evaluation.

Author Manuscript

In conclusion, this study provides strong inferences that a standard of care that includes
patient counseling on adherence, SMS messaging, and treatment supporters can improve
adherence for patients residing in Africa. As the provision of ART in Africa becomes more
long-term, sustainable efforts to promote adherence will be required. Future research should
consider evaluating other novel adherence interventions individually or in combination, not
only in adult populations but also in selected vulnerable populations where there is a large
knowledge gap such as children, adolescents, and pregnant women, as well as assess the
cost-effectiveness to inform policy-makers, clinicians and program managers.
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Search terms
(Human immunodeficiency virus OR HIV OR Acquired Immunodeficiency Syndrome OR
AIDS OR HIV Infection[MeSH])
AND
(antiretroviral OR anti-retroviral OR antiretroviral therapy OR highly active antiretroviral
therapy OR HAART OR Anti-HIV Agents OR Agents, Anti-HIV[MeSH])
AND

Author Manuscript

(patient compliance OR client compliance OR participant compliance OR adherence OR
Adherence, Medication[MeSH] OR Therapy, Directly Observed[MeSH] OR Compliance,
Patient[MeSH])
AND

Author Manuscript

(Algeria OR Angola OR Benin OR Botswana OR Burkina Faso OR Burundi OR Cameroon
OR Cape Verde OR Central African Republic OR Chad OR Comoros OR Congo OR Cote
d'Ivoire OR Cote OR Democratic Republic of the Congo OR Equatorial Guinea OR Eritrea
OR Ethiopia OR Gabon OR Gambia OR Ghana OR Guinea OR Guinea-Bissau OR Kenya
OR Lesotho OR Liberia OR Madagascar OR Malawi OR Mali OR Mauritania OR Mauritius
OR Mozambique OR Namibia OR Niger OR Nigeria OR Rwanda OR Sao Tome and
Principe OR Sao Tome OR Principe OR Senegal OR Seychelles OR Sierra Leone OR
Somalia OR South Africa OR Swaziland OR Togo OR Uganda OR United Republic of
Tanzania OR Tanzania OR Zambia OR Zimbabwe OR sub-saharan Africa OR subsaharan
africa OR africa, sub-saharan OR Africa OR East Africa OR West Africa OR Southern
Africa)
Appendix 2

List of studies excluded following full-text review
Study

Exclusion rationale

Byron, 200830
Cantrell,

200833

Holstad, 201235
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Idoko,

200721

Igumbor, 201131
Kabore,

201022

Kiweewa, 201336
Mansoor,

200634

Munyao, 201040
Pienaar,

200625

Not an RCT
Not an adherence intervention
Not an appropriate control group
Not an RCT
Not an RCT
Not an RCT
Endonodal trial
Follow-up less than 3 months
Substudy of Sarna51
Not an RCT
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Exclusion rationale

Pirkle,

200929

Not an RCT

Rich, 201232

Not an RCT

200428

Not an RCT

Sherr, 201023

Not an RCT

Roux,

Stubbs,

200924

Thurman, 201026
Torpey,

200827

Van Loggerenberg, 201037

Not an RCT
Not an RCT
Not an RCT
Adherence outcome not reported

Legend: endonodal refers to a trial that compares a form of an intervention to another form of the same intervention (eg.
dosing studies).
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0.82
(0.47, 1.37)
1.27
(0.73, 1.83)

0.85
(0.49, 1.41)

1.33
(0.76, 1.88)

1.24
(0.68, 1.84)
1.23
(0.96, 1.48)

2.64
(1.13, 3.49)

1.89
(1.32, 2.26)

1.21
(0.33, 2.50)
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(1.00, 2.06)

eSOC +
calendar

1.08
(0.53, 2.25)

1.65
(1.25, 1.93)

eSOC +
alarm

1.56
(0.89, 2.71)

1.08
(0.64, 1.82)

1.06
(0.69, 1.63)

Daily SMS

1.56
(0.89, 2.12)

Alarm

0.69
(0.41, 1.15)

1.57
(0.94, 2.61)

1.09
(0.67, 1.56)

1.08
(0.52, 1.81)

eSOC

1.23
(0.75, 1.73)

1.00
(0.60, 1.68)

Weekly
SMS

1.56
(1.01, 2.40)

1.65
(1.26, 2.17)

SOC +
weekly SMS

1.42
(0.86, 2.35)

2.07
(1.22, 3.53)

eSOC +
supporter

1.16
(0.54, 2.40)

1.26
(1.00, 1.58)

Note: Each cell represents the comparison (odds ratio and 95% CrI) of the row treatment versus the column treatment below the diagonal and of the column treatment versus the row treatment above the
diagonal.

Direct Effects

1.46
(1.06, 2.00)

SOC

Indirect Effects
1.83
(1.36, 2.47)
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Direct versus indirect evidence for adherence to ART among HIV-positive patients, ITT analysis
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1.78
(0.93–3.44)
1.98
(0.95–4.26)

1.32
(0.85–2.06)
1.47
(0.89–2.45)

1.73
(1.31–2.30)
1.94
(1.13–3.35)
2.10
(1.54–2.86)

Weekly SMS

Enhanced SOC +
weekly SMS

Enhanced SOC +
treatment supporter

2.15
(1.15–3.99)

1.27
(0.51–3.08)
1.38
(0.62–3.01)

0.72
(0.33–1.47)

1.14
(0.47–2.65)

0.72
(0.28–1.83)

Enhanced
SOC +
calendar

0.66
(0.28–1.53)

0.59
(0.27–1.25)

0.38
(0.16–0.86)

0.52
(0.19–1.49)

Enhanced
SOC +
alarm

1.91
(1.10–3.35)

1.76
(0.87–3.58)

1.58
(1.00–2.51)

Daily SMS

1.21
(0.80–1.85)

1.12
(0.61–2.06)

Weekly
SMS

1.08
(0.62–1.87)

Enhanced
SOC +
weekly
SMS

An odds ratio greater than 1.00 indicates an estimated increased odds of adherence for the intervention along the vertical axis in the first column, whereas an odds ratio less than 1.00 indicates an estimated
decreased odds of adherence for the regimen along the vertical axis in the first column. Bolded results indicate statistically significant relationships.

1.59
(1.19–2.15)

1.12
(0.54–2.38)

0.84
(0.47–1.47)

1.10
(0.69–1.74)

Daily SMS

1.56
(0.61–4.18)

1.15
(0.55–2.50)

1.52
(0.68–3.51)

Enhanced SOC +
calendar

3.00
(1.42–6.54)

2.22
(1.09–4.64)

2.92
(1.47–6.04)

Enhanced SOC +
alarm

0.74
(0.41–1.34)

0.97
(0.54–1.75)

Alarm

Alarm

1.31
(0.93–1.85)

Enhanced
SOC

Enhanced SOC

Standard of
Care (SOC)

Odds ratios and 95% credibility intervals for adherence to ART among HIV-positive patients, per-protocol analysis
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Appendix 5

Results of pairwise meta-analyses of comparisons of adherence interventions

Comparison

N Arms

Pairwise comparison

Network meta-analysis

OR (95% CI)

OR (95% CI)

Author Manuscript

Enhanced SOC vs SOC

2

1.24 (0.76–2.03)

1.46 (1.06–1.98)

Alarm vs SOC

1

0.85 (0.49–1.48)

1.00 (0.60–1.67)

Enhanced SOC + alarm vs SOC

1

1.33 (0.76–2.32)

1.57 (0.94–2.62)

Daily SMS vs SOC

1

1.89 (0.67–1.75)

1.06 (0.68–1.64)

Weekly SMS vs SOC

2

1.65 (1.15–2.28)

1.65 (1.25–2.18)

Enhanced SOC + weekly SMS vs SOC

1

2.64 (1.13–6.16)

2.07 (1.22–3.53)

Enhanced SOC + treatment supporter vs SOC

2

2.58 (1.71–3.89)

1.83 (1.36–2.45)

Alarm vs enhanced SOC

1

0.82 (0.47–1.43)

0.69 (0.41–1.14)

Enhanced SOC + alarm vs enhanced SOC

1

1.27 (0.73–2.23)

1.26 (1.00–1.58)

Enhanced SOC + calendar vs enhanced SOC

1

1.08 (0.52–2.25)

1.25 (0.67–2.57)

Enhanced SOC + weekly SMS vs enhanced SOC

1

1.24 (0.68–2.26)

1.42 (0.86–2.35)

Enhanced SOC + treatment supporter vs enhanced
SOC

5

1.13 (0.88–1.46)

1.26 (1.00–1.58)

Enhanced SOC + alarm vs alarm

1

1.55 (0.89–2.72)

1.56 (0.89–2.74)

Enhanced SOC + treatment supporter vs enhanced
SOC +
calendar

1

1.21 (0.33–4.38)

1.01 (0.48–1.93)

Weekly SMS vs daily SMS

1

1.59 (1.00–2.53)

1.56 (1.01–2.40)
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0.61
(0.34, 1.21)

1.37
(1.01, 1.67)

1.55
(1.00, 1.98)
1.31
(0.52, 2.23)

Alarm

0.99
(0.12, 7.26)

Weekly SMS

1.55
(0.21, 12.18)

eSOC +
treatment
supporter

1.07
(0.28, 3.81)

SOC +
supporter

0.61
(0.33, 1.11)

Note: Each cell represents the comparison (odds ratio and 95% CrI) of the row treatment versus the column treatment below the diagonal and of the column treatment versus the row treatment above the
diagonal.

Direct comparisons

eSOC

2.62
(0.91, 3.67)
0.99
(0.51, 1.64)

1.45
(0.37, 7.43)

SOC

1.54
(0.45, 6.10)

Author Manuscript
Indirect comparisons

Author Manuscript

Direct vs indirect evidence for viral suppression

Author Manuscript
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Research in Context Panel
Systematic Review
We conducted a systematic search of the medical literature for relevant randomized
clinical trials that described interventions to improve adherence to ART among HIVpositive patients, using terms for “HIV”, “ART”, “adherence” and “Africa”. The search
was conducted using the following electronic databases: AMED, CINAHL, EMBASE,
MEDLINE (via PubMed), and Clinicaltrials.gov from inception to December 2013. We
identified 14 RCTs for our analysis that met our study’s inclusion/exclusion criteria.
Interpretation

Author Manuscript

We found compelling evidence that enhanced standard of care improved patient
adherence. This was further improved when combined with weekly SMS messages and
treatment supporters. As the provision of ART in Africa becomes increasingly available,
effective interventions to promote adherence will be necessary to generate sustainable
ART delivery.
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Box 1
Population, interventions, comparisons, outcomes and study design (PICOS) criteria for
study inclusion.

Criteria

Definition

Population

Adult HIV+ patients on ART in Africa

Interventions

Any intervention to improve adherence to ART

Comparisons

Standard of care or another intervention to improve adherence to ART

Outcomes

Any measurement of adherence to ART

Study Design

RCT with minimum 3 months of follow-up

Author Manuscript

Treatment definitions used for categorization of interventions in the network meta-analysis

Author Manuscript

Criteria

Definition

Standard of Care
(SOC)

Usual standard of care

Enhanced SOC
(eSOC)

Usual standard of care, plus intensified adherence counseling

Alarm

Participants received a pocket alarm device which they were to carry around at all
times; this device was programmed to beep and flash twice a day to remind
patients to take their medication

eSOC + alarm

Enhanced SOC plus the pocket alarm device as described above

eSOC + calendar

In addition to enhanced SOC, patients were given a treatment calendar containing
educational messages about ART and adherence; patients were to record when
they took their medication in the calendar

Daily SMS

Daily text message sent to the patient’s cell phone (their own or one provided by
the study) – with or without ability for patient to respond to care provider

Weekly SMS

Weekly text message sent to the patient’s cell phone (their own or one provided by
the study) – with or without ability for patient to respond to care provider

eSOC + weekly SMS

Weekly text message sent to the patient’s cell phone (their own or one provided by
the study) in addition to enhanced SOC

eSOC + treatment
supporter

Treatment supporter (chosen by individual or assigned by clinic) in addition to
enhanced SOC

SOC + treatment
supporter

Treatment supporter (chosen by individual or assigned by clinic) in addition to
SOC
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Figure 1.

Flow diagram of study selection.
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Figure 2.

Network diagram for randomized clinical trials evaluating interventions seeking to improve
ART adherence among HIV-positive patients
Legend. Nodes represent the individual or combined interventions. Lines between the nodes
represent where direct (head-to-head) RCTs have been conducted. The numbers within those
lines indicate the number of RCTs that have been conducted.
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Figure 3.

Network diagram for randomized clinical trials evaluating viral suppression between
interventions seeking to improve ART adherence among HIV-positive patients.
Legend. Nodes represent the individual or combined interventions. Lines between the nodes
represent where direct (head-to-head) RCTs have been conducted. The numbers within those
lines indicate the number of RCTs that have been conducted.
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78 weeks

48 weeks

28 weeks

26–52
weeks

17 weeks

26 weeks

52 weeks

Kenya

Brazil,
Botswana,
Haiti, Peru,
South Africa,
Uganda,
Zambia,
Zimbabwe

Uganda

Kenya

Nigeria

Cameroon

Tanzania

Gross, 2014

Kunutsor, 2011

Lester, 2010

Maduka, 2012

Mbuagbaw,
2012

Mugusi, 2009

192 weeks

Uganda

Chang, 2010

Chung, 2011

Trial
duration

Trial
location

Trial
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No missed dose (self-report)

≥ 95% adherence, no
missed dose (self-report)

≥ 95% adherence

≥ 95% adherence

≥ 95% adherence

% doses taken (not used
in adherence analysis)

≥ 95% adherence

≥ 95% adherence;
100% adherence;
no missed dose (selfreport)

Measures of adherence
66%

34.0 (17–70)a
35.5 (15–76)

eSOC
eSOC + treatment supporter

66%
51%
48%

66%
71%
66%
65%
56%
44%
79%
68%
69%

36 (31–44)
36 (32–41)
38 (32–44)
37 (33–45)e
38 (34–44)

39.2 (8.4)b
39.1 (8.3)
36.7 (19–65)c
36.6 (22–84)
35.3 (9.0)b
36.6 (11.8)
39.0 (10.0)b
41.3 (10.1)
39.9 (8.8)b
39.5 (8.7)

eSOC
Alarm
eSOC + alarm
SOC
SOC + treatment supporter

eSOC
eSOC + treatment supporter
SOC
Weekly SMS
SOC
eSOC + weekly SMS
eSOC
eSOC + weekly SMS
eSOC
eSOC + calendar

61%

68%

59%

35 (30–40)a

SOC

71%

%
Women

Age

Comparisons

242

312

101

99

52

52

273

265

87

87

129

128

100

100

100

100

970

366

N patients

Characteristics and outcomes of included trials reporting on adherence interventions for HIV-positive patients on ART

229

294

72/80

66/78

40

29

168

132

80

71

NR

NR

58

47

52

51

862/651/716

322/253/265

N adherent
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Mean(standard deviation);

Mean;

SOC: standard of care; eSOC: enhanced standard of care.

Median(interquartile range);

e

d

58%
58%
61%
70%
53%

35.7 (9.7)b
36.7 (9.2)
37.1 (9.8)b
36.6 (9.4)
35.6d
36.1

SOC
eSOC + treatment supporter
SOC
eSOC
eSOC
eSOC + treatment supporter

37.3 (8.0)

eSOC + treatment supporter

eSOC + treatment supporter

34.2 (8.9)

64%

37 (7.8)b

eSOC

SOC

64%

37.3

Weekly SMS

66%

63%

64%

68%

35.7

Daily SMS

66%

35.6

SOC

54%

58%

37.8 (14.6)

eSOC + treatment supporter

%
Women

Age

Comparisons

The duration of this trial was 48 weeks. Results at 24 weeks were used because after 24 weeks the SOC arm was switched to eSOC.

Mean(range);

c

≥ 95% adherence

24 weeks*

Nigeria

Taiwo, 2010

Median (range);

b

a

*

≥ 95% adherence

72 weeks

Kenya

Sarna, 2008

≥ 90% adherence

48 weeks

Kenya

Pop-Eleches,
2011

100% adherence

52 weeks

No missed dose (selfreport)

Mozambique

17 weeks

South Africa

Peltzer, 2012

≥ 95% adherence

Measures of adherence

Pearson, 2007

104 weeks

South Africa

Nachega, 2010

Author Manuscript
Trial
duration

Author Manuscript

Trial
location

248

251

116

118

147

142

139

175

175

76

76

137

137

67

N patients

Author Manuscript

Trial

220

181

75

85

78

59

55

151

143

71

65

126

120

64

N adherent
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1.06
(0.54–2.07)
1.64
(0.93–2.94)
2.06
(1.03–4.11)
1.82
(1.08–3.10)

1.25
(0.67–2.57)
0.73
(0.43–1.24)
1.14
(0.75–1.72)
1.42
(0.86–2.35)
1.26
(1.00–1.58)

1.81
(0.91–3.96)
1.06
(0.68–1.64)
1.65
(1.25–2.18)
2.07
(1.22–3.53)
1.83
(1.36–2.45)

eSOC + calendar

Daily SMS

Weekly SMS

eSOC + weekly SMS

eSOC + treatment
supporter

1.17
(0.69–1.98)

1.32
(0.66–2.63)

1.05
(0.58–1.88)

0.68
(0.34–1.32)

1.16
(0.52–2.77)

eSOC +
alarm

1.01
(0.48–1.93)

1.14
(0.47–2.52)

0.91
(0.40–1.92)

0.58
(0.24–1.32)

eSOC +
calendar

1.73
(1.02–2.94)

1.95
(0.98–3.89)

1.56
(1.01–2.40)

Daily SMS

1.11
(0.74–1.67)

1.25
(0.69–2.29)

Weekly
SMS

0.88
(0.52–1.50)

eSOC +
weekly
SMS

SOC: standard of care; eSOC: enhanced standard of care. An odds ratio greater than 1.00 indicates an estimated increased odds of adherence for the intervention along the vertical axis in the first column,
whereas an odds ratio less than 1.00 indicates an estimated decreased odds of adherence for the regimen along the vertical axis in the first column. Bolded results indicate statistically significant relationship.

1.81
(0.82–4.36)

1.08
(0.65–1.80)

1.57
(0.94–2.62)

eSOC + alarm

1.56
(0.89–2.74)

0.69
(0.41–1.14)

1.00
(0.60–1.67)

Alarm

Alarm

1.46
(1.06–1.98)

eSOC

eSOC

SOC

Odds ratios and 95% credibility intervals for adherence to ART among HIV-positive patients

Author Manuscript

Table 2
Mills et al.
Page 26

Lancet HIV. Author manuscript; available in PMC 2016 November 04.

Author Manuscript

Author Manuscript

Author Manuscript

SOC: standard of care; eSOC: enhanced standard of care.

0.62
(0.25, 1.49)

0.46
(0.21, 1.00)

0.61
(0.33, 1.11)

SOC + treatment
supporter

1.48
(0.72–3.00)

1.12
(0.71–1.73)

eSOC + treatment
supporter

1.46
(1.09–1.97)

1.55
(1.01–2.38)

Weekly SMS

0.75
(0.33–1.72)

Alarm

1.57
(0.71–3.42)

0.99
(0.51–1.93)

Alarm

eSOC

1.18
(0.61–2.25)

1.32
(0.80–2.18)

eSOC

SOC

0.39
(0.19, 0.83)

0.94
(0.56–1.60)

Weekly
SMS

0.42
(0.21, 0.81)

eSOC +
treatment
supporter

Odds ratios and 95% credibility intervals - viral suppression (<400 copies/ml) at last reported time point.
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